首页> 外文期刊>Human vaccines & immunotherapeutics. >Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates
【24h】

Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates

机译:破伤风类毒素,白喉类毒素和交叉反应物质197(CRM197)在糖缀合物中用作载体蛋白时的潜在保护性免疫原性

获取原文
获取原文并翻译 | 示例
           

摘要

When tetanus toxoid (TT), diphtheria toxoid (DT) or Cross Reacting Material 197 (CRM197), a non-toxic diphtheria toxin mutant protein, are used as carrier proteins in glycoconjugate vaccines, these carriers induce a protein specific antibody response as measured by in vitro assays. Here, it was evaluated whether or not glycoconjugates based on TT, DT or CRM197 can induce a protective immune response as measured by potency tests according to the European Pharmacopoeia. It could be shown, that the conjugate carriers TT and DT can induce a protective immune response against a lethal challenge by toxins in animals, while glycoconjugates based on CRM197 failed to induce a protective immune response. Opportunities for new applications of glycoconjugates are discussed.
机译:当破伤风类毒素(TT),白喉类毒素(DT)或交叉反应物质197(CRM197)(一种无毒白喉毒素突变蛋白)用作糖缀合物疫苗中的载体蛋白时,这些载体可诱导蛋白质特异性抗体反应,如体外测定。在此,根据欧洲药典,通过效能测试测定,评估了基于TT,DT或CRM197的糖缀合物是否可以诱导保护性免疫应答。可以证明,缀合物载体TT和DT可以诱导针对动物毒素致死性攻击的保护性免疫应答,而基于CRM197的糖缀合物不能诱导保护性免疫应答。讨论了糖缀合物新应用的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号